We are the first to demonstrate that there is a dramatic increase in JAK3 protein levels as well as in its phosphorylation/activation state during the acute phase of ischemic stroke and that inhibiting JAK3 is ineffective at reducing stroke size compared to vehicle-treated animals using a comprehensive dose–response curve. Here, JAK3 is linked to stroke disorder.